| License: Creative Commons Attribution 4.0 PDF - Published Version (30MB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-520873
- DOI to cite this document:
- 10.5283/epub.52087
Abstract
Oral cancer often presents with aggressive behavior and a high risk of recurrence and metastasis. For oral squamous cell carcinoma (OSCC), which is the most frequent histological subtype, therapy strategies include surgery, radiation therapy, chemotherapy, immune checkpoint inhibitors, and EGFR inhibitors. Recently, a Trop-2 antibody-drug conjugate (ADC) has been approved in the United States of ...
Owner only: item control page